Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PGNY 
Progyny Inc (PGNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/15/2025: PGNY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $26.25
1 Year Target Price $26.25
| 4 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.42% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.01B USD | Price to earnings Ratio 41.18 | 1Y Target Price 26.25 |
Price to earnings Ratio 41.18 | 1Y Target Price 26.25 | ||
Volume (30-day avg) 10 | Beta 1.32 | 52 Weeks Range 13.39 - 30.42 | Updated Date 07/15/2025 |
52 Weeks Range 13.39 - 30.42 | Updated Date 07/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.33% | Operating Margin (TTM) 7.46% |
Management Effectiveness
Return on Assets (TTM) 5.99% | Return on Equity (TTM) 10.11% |
Valuation
Trailing PE 41.18 | Forward PE 15.04 | Enterprise Value 1781677140 | Price to Sales(TTM) 1.66 |
Enterprise Value 1781677140 | Price to Sales(TTM) 1.66 | ||
Enterprise Value to Revenue 1.47 | Enterprise Value to EBITDA 23.24 | Shares Outstanding 85718000 | Shares Floating 79364609 |
Shares Outstanding 85718000 | Shares Floating 79364609 | ||
Percent Insiders 7.64 | Percent Institutions 98.36 |
Upturn AI SWOT
Progyny Inc
Company Overview
History and Background
Progyny Inc. was founded in 2008 and went public in 2019. It focuses on providing comprehensive fertility benefits solutions to employers. It has grown significantly by offering specialized and high-quality services in the fertility benefits management space.
Core Business Areas
- Fertility Benefits Management: Offers a comprehensive fertility benefits solution that includes access to a network of fertility specialists, personalized support through patient care advocates (PCAs), and an integrated pharmacy benefits program.
Leadership and Structure
Pete Anevski is the CEO. The company has a typical corporate structure with departments for sales, marketing, operations, technology, and finance. Board of Directors are responsible for overseeing the company's strategy and performance.
Top Products and Market Share
Key Offerings
- Progyny Fertility Benefit: Provides access to a comprehensive fertility benefits solution, including IVF, IUI, and egg freezing. Progyny claims to have superior outcomes and lower costs compared to traditional plans. Competitors include Carrot Fertility and WINFertility. Progyny does not publish the revenue specifically from fertility benefits but it makes up most of their overall revenue.
- Progyny Rx: Integrated pharmacy benefits solution focused on fertility medications, offering cost-effective and convenient access. Competitors include traditional pharmacy benefit managers (PBMs) like CVS Caremark and Express Scripts. Progyny does not publish the revenue specifically from Progyny Rx but it makes up a decent portion of their overall revenue.
Market Dynamics
Industry Overview
The fertility benefits market is growing due to increasing infertility rates, greater employer focus on diversity and inclusion, and the rising acceptance of fertility treatments. The industry is competitive, with several players offering various solutions.
Positioning
Progyny Inc. is positioned as a premium fertility benefits provider with a focus on quality, clinical outcomes, and cost-effectiveness. Its key competitive advantages include its network of specialists, personalized support, and integrated pharmacy benefits.
Total Addressable Market (TAM)
The TAM for fertility benefits is estimated to be several billion dollars annually and growing. Progyny is well positioned to capture a significant share of this market due to its leading position, brand recognition, and focus on outcomes.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- High client retention rates
- Demonstrated clinical success
- Integrated benefits platform
Weaknesses
- High customer concentration
- Reliance on employer-sponsored benefits
- Premium pricing compared to some competitors
Opportunities
- Expanding into new markets and geographies
- Developing new fertility-related services
- Forming strategic partnerships with healthcare providers
- Increased employer adoption of fertility benefits
Threats
- Competition from other fertility benefits providers
- Changes in healthcare regulations
- Economic downturn impacting employer budgets
- Technological advancements rendering current services obsolete
Competitors and Market Share
Key Competitors
- Carrot Fertility (Private)
- WINFertility (Private)
- Teladoc Health (TDOC)
Competitive Landscape
Progyny Inc. has a competitive advantage in terms of brand recognition, clinical outcomes, and integrated benefits platform. It faces competition from other fertility benefits providers and traditional healthcare companies.
Growth Trajectory and Initiatives
Historical Growth: Progyny Inc. has experienced strong historical revenue growth driven by increased adoption of fertility benefits by employers.
Future Projections: Analysts project continued revenue growth for Progyny Inc., driven by increased market penetration and new product offerings.
Recent Initiatives: Recent strategic initiatives include expanding into new markets, developing new product offerings, and forming strategic partnerships.
Summary
Progyny is a leading fertility benefits provider, demonstrating strong revenue growth and a commitment to clinical outcomes. Its focus on employer-sponsored benefits makes it vulnerable to economic downturns. While client concentration poses a risk, expanding service offerings and exploring new partnerships could drive future success. The competitive landscape requires constant innovation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Company Website
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market data is subject to change. Market share data are based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Progyny Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-10-25 | CEO & Director Mr. Peter Anevski CPA | ||
Sector Healthcare | Industry Healthcare Plans | Full time employees 675 | Website https://www.progyny.com |
Full time employees 675 | Website https://www.progyny.com | ||
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.